Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published March 1, 1986 | Published
Journal Article Open

Primary Structure of the Human Melanoma-Associated Antigen p97 (Melanotransferrin) Deduced from the mRNA Sequence

Abstract

p97 is a cell-surface glycoprotein that is present in most human melanomas but only in trace amounts in normal adult tissues. To determine the structure of this tumor-associated antigen and to identify its functional domains, we have purified and cloned p97 mRNA and determined its nucleotide sequence. The mRNA encodes a 738-residue precursor, which contains the previously determined N-terminal amino acid sequence of p97. After removal of a 19-residue signal paptide, the mature p97 molecule comprises extracellular domains of 342 and 352 residues and a C-terminal 25-residue stretch of predominantly uncharged and hydrophobic amino acids, which we believe acts as a membrane anchor. Each extracellular domain contains 14 cysteine residues, which form seven intradomain disulfide bridges, and one or two potential N-glycosylation sites. Protease digestion studies show that the three major antigenic determinants of p97 are present on the N-terminal domain. The domains are strikingly homologous to each other (46% amino acid sequence homology) and to the corresponding domains of human serum transferrin (39% homology). Conservation of disulfide bridges and of amino acids thought to compose the iron binding pockets suggests that p97 is also related to transferrin in tertiary structure and function. We propose that p97 be renamed melanotransferrin to denote its original identification in melanoma cells and its evolutionary relationship to serotransferrin and lactotransferrin, the other members of the transferrin superfamily.

Additional Information

© 1986 by the National Academy of Sciences Communicated by Hans Neurath, October 21, 1985 We are grateful to Drs. Stanley McKnight, Richard Gelinas, Gregory Barsh, Steven Henikoff, and David Lee for their advice and encouragement and to Toni Monsey, Cynthia Green, and Jan Conitz for their excellent technical assistance. This investigation was supported by National Cancer Institute Grants CA 34777 and 38415 and by National Institutes of Health Grant GM 07266. The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Attached Files

Published - ROSpnas86.pdf

Files

ROSpnas86.pdf
Files (1.1 MB)
Name Size Download all
md5:94ed6f7a728ccf42a4aa8d147e44977c
1.1 MB Preview Download

Additional details

Created:
August 22, 2023
Modified:
October 16, 2023